J&J
myeloma drug, in combo regimen, delays worsening of the disease
Send a link to a friend
[June 06, 2016]
By Ransdell Pierson
(Reuters) - Johnson & Johnson's therapy for
advanced multiple myeloma sharply reduced the risk of disease
progression when taken with two standard treatments for the blood
cancer, according to research the company hopes will pave the way for
wider use of the treatment.
|
The drug, Darzalex, received U.S. approval in November for use by
itself among patients who had received at least three prior
treatments for myeloma, a cancer of infection-fighting white blood
cells.
Data from a late-stage trial involving 498 patients who had
previously undergone one or more myeloma treatments was released on
Sunday. In the study, one group received Takeda Pharmaceutical Co's
Velcade and the steroid dexamethasone, while the other group
received Darzalex in combination with those two drugs.
After more than seven months, 61 percent fewer patients taking the
Darzalex combination experienced a worsening of their disease
compared with those taking the standard two-drug regimen, meeting
the trial's main goal. The median time to progression of disease has
not yet been reached for the Darzalex group, compared with 7.2
months for patients taking the two-drug combo.
The study was stopped in March after an independent data monitoring
committee found the Darzalex regimen showed a statistically
significant benefit.
Some 19 percent of patients in the Darzalex group showed no further
sign of disease, versus 9 percent of those taking Velcade and
dexamethasone. Significant disease reduction was seen in 83 percent
taking the Darzalex regimen, versus 63 percent in the two-drug
combination.
The findings were presented at the annual meeting of the American
Society of Clinical Oncology, in Chicago.
The infused medicine, which has a list price of $135,000 for the
first full year of treatment, blocks the CD38 protein found on
myeloma cells. It was approved based on favorable data from two
smaller trials, including a study in which tumors shrank in 29
percent of patients.
Dr. Antonio Palumbo, the study's lead researcher, said in an
interview that overall toxicity in the Darzalex regimen was similar
to that seen with the two standard treatments. That may help the J&J
drug become a second-line treatment, in combination with Velcade and
dexamethasone, he said.
[to top of second column] |
The most common side effects for both drug combinations included low
blood platelets, diarrhea and anemia.
Palumbo, melanoma unit chief at the University of Torino, Italy,
said data from another late-stage study of Darzalex is expected
later this month and will probably mirror strong results seen in his
own study.
In that trial, patients received Darzalex in combination with
Celgene Corp's leading Revlimid (lenalidomide) treatment and with
dexamethasone.
Mark Wildgust, global head of hematology at J&J, said the company
hopes the trial results will allow it to market Darzalex as an
earlier treatment, and in combination with standard medicines.
The National Cancer Institute estimates there are 26,850 new cases
of multiple myeloma each year in the United States. The average life
expectancy is four years.
(Reporting by Ransdell Pierson; Editing by Leslie Adler)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|